Radio Frequency Ablation Device Market Observes an Outstanding Growth during the Forecast period 2022-2028

 

Radio Frequency Ablation Device Market

Patients with heart illnesses (such as atrial fibrillation (AF), atrial flutter, and cardiac arrhythmias), cancer, and pain management might benefit from radiofrequency ablation (RFA). Because of its great effectiveness, simplicity of administration, and safety, it has become a preferred approach. RFA is rapidly being utilised to treat a variety of disorders, including cancer and cardiac arrhythmia. The rise in the frequency of cardiovascular disorders such as atrial fibrillation, the incidence of patients suffering from cancer and pain, and the need for minimally invasive treatments are all driving market expansion.

A Radio Frequency Ablation Device is an electrical conduction system that converts electromagnetic energy into heat energy by using a high-frequency alternating current. Radiofrequency ablation is a minimally invasive procedure that uses imaging techniques such as magnetic resonance imaging, ultrasound, and computed tomography to treat medical diseases such as cancer tumours. By eliminating the obstructive tissues and nerves, radiofrequency ablation devices employ non-surgical treatments to kill cancerous cells.

The procedure is inserting a needle into the tumour via the skin to target the aberrant tissues with radio-frequency electrical energy, which causes the tumour to heat up through an active electrode tip. Oncology, brain tumours, gynaecology, cardiac rhythm and renal denervation for hypertension, pain management, and cosmetology are just a few of the medical domains where radiofrequency ablation technology is used.

The utilisation of ultrasonic ablation technology in RFADs is also helping to boost their appeal. The market, however, is constrained by high treatment costs, insufficient knowledge of the technique, and the availability of alternative therapies. Drivers are projected to have a greater influence than constraints, according to estimates. Furthermore, there are attractive development potential in emerging markets, undiscovered markets in developing countries, and technology improvements in RFA.

Due to an increase in the prevalence of heart disorders such as atrial fibrillation (AF), atrial flutter, cardiac arrhythmias, and others, the radiofrequency ablation devices business is developing. As a result, several mid-to-large-sized corporations have increased their R&D efforts in this industry. Furthermore, smaller firms have moved their attention in the Radio Frequency Ablation Device Market to increasing R&D operations, resulting in a high number of product innovations (approvals & launches) and, as a consequence, contributing to market growth.

Due to the vast number of small- to mid-sized firms making RF devices, acquisition was another significant tactic used by larger companies to purchase smaller and developing enterprises. This is evidenced by Boston Scientific Corporation's strategic acquisition of Cosman Medical, Inc., a large maker of radiofrequency ablation devices, in July 2016. The Cosman Medical team and products will be integrated into the Boston Scientific Neuromodulation business, which provides a comprehensive variety of spinal cord stimulator (SCS) and deep brain stimulation devices for the treatment of Parkinson's disease, dystonia, and essential tremor.

Key players of the radiofrequency ablation device market include Boston Scientific, St Jude Medical, Medtronic, Covidien and Stryker. Other prominent vendors include Imricor Medical Systems, AtriCure, BIOTRONIK, MicroPort Scientific and Spacelabs Healthcare.